GPBAR1 and metabolic dysfunction-associated steatotic liver disease: Given that ALD shares many pathophysiological features with NAFLD during liver disease progression (Table 1), it is thus highly plausible to speculate that GPCR signaling pathways are either directly or indirectly involved in the pathogenesis of ALD and may also serve as promising therapeutic targets.